VALERIE SHIN: Open Payments
NPI 1164906822 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,073 in 25 payments from 9 companies in 2025. Trend: 2023 $965 · 2024 $988 · 2025 $4,073
Consulting: $2,250Food & beverage: $1,246Travel & lodging: $577
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $3,085 |
| Gilead Sciences, Inc. | 7 | $314 |
| Mirum Pharmaceuticals, Inc. | 1 | $142 |
| Madrigal Pharmaceuticals | 1 | $136 |
| Ipsen Biopharmaceuticals, Inc | 2 | $126 |
| Novo Nordisk Inc | 1 | $125 |
| Tempus AI, Inc | 1 | $97 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
Products named: TRULANCE, Livmarli, REZDIFFRA, Wegovy, Livdelzi, XIFAXAN, IQIRVO, XT CDX.
Industry payments across CA — which companies pay providers there.
